Therapy Areas: Respiratory
CStone wins EU approval for lung cancer drug
26 July 2024 - Biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) on Friday announced European Commission approval of sugemalimab (Cejemly) in combination with platinum-based chemotherapy fo...
Precigen names new chief commercial officer
24 July 2024 - US biopharmaceutical company Precigen Inc (Nasdaq: PGEN) announced on Tuesday the appointment of Phil Tennant as its new chief commercial officer.In this role Tennant will be responsibl...
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
22 July 2024 - Clinical-stage biopharmaceutical company Nuvalent, Inc. (Nasdaq:NUVL) announced on Monday the initiation of HEROEX-1, a Phase 1a/1b clinical trial for NVL-330.NVL-330 is a novel HER2-se...
AstraZeneca completes acquisition of Amolyt Pharma
15 July 2024 - Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that it has successfully finalised its acquisition of Amolyt Pharma, a clinical-stage biote...
Genentech ends trial as combination therapy fails to meet efficacy endpoints in lung cancer
4 July 2024 - Biotechnology company Genentech, part of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), revealed on Thursday that its Phase II/III SKYSCRAPER-06 trial testing a combination therapy for l...
Insmed Incorporated to present positive brensocatib data at World Bronchiectasis Conference
3 July 2024 - Biopharmaceutical company Insmed Incorporated (Nasdaq: INSM) announced on Wednesday that additional positive results from the ASPEN study of brensocatib in patients with bronchiectasis w...